Literature DB >> 9764617

The cost-effectiveness of routine type and screen admission testing for expected vaginal delivery.

S B Ransom1, G Fundaro, M P Dombrowski.   

Abstract

OBJECTIVE: To evaluate the cost effectiveness of routine admission type and screen testing for expected vaginal delivery.
METHODS: A retrospective review was conducted in patients transfused with blood during an admission that anticipated a vaginal delivery over a 3-year period, at Hutzel Hospital, in Detroit, Michigan.
RESULTS: Of 16,291 patients admitted for an expectant vaginal delivery, 76 (.47%) (95% confidence interval [CI] .37%, .58%) required blood transfusion during the time of their admission. Medical records of these 76 patients were evaluated as to urgency and risk factors. Most of the blood transfusions were related to previously identified risk factors, including previous postpartum hemorrhage, multiple pregnancies, previous cesarean delivery, abruptio placentae, and admission anemia. Four patients received an urgent blood transfusion without a previously identifiable risk factor. We found an overall urgent blood transfusion rate without admission risk factors to be 2.5 per 10,000 vaginal deliveries (95% CI .9 per 10,000, 6.3 per 10,000)
CONCLUSION: Routine admission type and screen testing for an expected normal vaginal delivery does not seem to enhance patient care and should be eliminated for patients without substantial risk factors. In the rare event that a patient without a previously identified risk factor required an urgent blood transfusion, O negative blood could be given in the interim pending formal type and cross match.

Entities:  

Mesh:

Year:  1998        PMID: 9764617     DOI: 10.1016/s0029-7844(98)00288-9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  1 in total

1.  Routine preoperative typing and screening: a safeguard or a misuse of resources.

Authors:  Silvio Fabian Ghirardo; Ishwaria Mohan; Alicia Gomensoro; Mitchell I Chorost
Journal:  JSLS       Date:  2010 Jul-Sep       Impact factor: 2.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.